Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of adjuvant S-1 plus oxaliplatin (SOX) duration in stage III colon cancer
jRCTs031180109Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin and tegafur in colon cancer (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Disease-free survival. Started Apr 2014; status: completed.
02
Drugs
oxaliplatintegafur
03
Conditions
colon cancer
Beyond the preview
Go deeper on jRCTs031180109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180109.